Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer | |
Wang, Wenxian4,5,6; Huang, Zhangzhou1; Yu, Zongyang9; Zhuang, Wu1; Zheng, Weijun8; Cai, Zhijian7; Shi, Lei2; Yu, Xinmin4,5,6; Lou, Guangyuan4,5,6; Hong, Wei4,5,6 | |
刊名 | FRONTIERS IN ONCOLOGY |
2020-10-09 | |
卷号 | 10 |
关键词 | immune checkpoint inhibitor non-small cell lung cancer biomarker chemotherapy lung immune prognostic index |
ISSN号 | 2234-943X |
DOI | 10.3389/fonc.2020.572853 |
通讯作者 | Chen, Ming(chenming@zjcc.org.cn) ; Song, Zhengbo(songzb1983@163.com) |
英文摘要 | Background Lung immune prognostic index (LIPI) status was recently developed to predict responses to immune checkpoint inhibitor (ICI) treatments. However, it is unclear whether LIPI is a prognostic index for both patients treated with ICI monotherapy and patients treated with ICIs combined with chemotherapy (ICIs CC). Methods This retrospective study established the patterns of LIPI in Chinese patients with advanced non-small cell lung cancer. Lung immune prognostic index based on the derived neutrophil-to-lymphocyte ratio greater than 3 and lactate dehydrogenase greater than the upper limit of normal was developed to characterize good, intermediate, or poor LIPI status. Associations between LIPI status and progression-free survival (PFS) and overall survival (OS) were analyzed. Kaplan-Meier curves and Cox proportional hazards models were used to determine survival differences. Results Three hundred thirty patients were included in this study. Of these patients, 216 received ICI monotherapy and 114 received ICIs CC. A good LIPI status was associated with better PFS (6.1 months vs. 2.3 months vs. 2.1 months, P = 0.023) and OS (24.2 months vs. 14.5 months vs. 9.3 months, P < 0.001) in ICI monotherapy compared to intermediate or poor LIPI status. No differences in PFS (17.9 vs. 9.9 months vs. 7.6 months, P = 0.355, respectively) and OS (P = 0.346) were observed in patients who received ICIs CC. Moreover, we found that patients who had an improved LIPI status compared with the baseline value had a longer PFS with ICI monotherapy and LIPI intermediate status (8.4 months vs. 2.1 months vs. 1.4 months, P < 0.001). However, in patients treated with ICIs CC, these dynamic changes were not observed (P = 0.444). Conclusions Lung immune prognostic index status and dynamic changes in LIPI could be prognostic markers of treatment response to ICI monotherapy, but not to ICIs CC. In particular, good LIPI status was associated with a better clinical outcome compared with intermediate and poor LIPI status in ICI monotherapy treatment. |
资助项目 | National Natural Science Foundation of China[81802276] |
WOS关键词 | TO-LYMPHOCYTE RATIO ; SERUM LACTATE-DEHYDROGENASE ; EARLY MARKER ; OPEN-LABEL ; NSCLC ; OUTCOMES ; PEMBROLIZUMAB ; ASSOCIATION ; THERAPY ; IMMUNOTHERAPY |
WOS研究方向 | Oncology |
语种 | 英语 |
出版者 | FRONTIERS MEDIA SA |
WOS记录号 | WOS:000581168900001 |
资助机构 | National Natural Science Foundation of China |
内容类型 | 期刊论文 |
源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/104600] |
专题 | 中国科学院合肥物质科学研究院 |
通讯作者 | Chen, Ming; Song, Zhengbo |
作者单位 | 1.Fujian Med Univ, Fujian Prov Canc Hosp, Dept Med Oncol, Canc Hosp, Fuzhou, Peoples R China 2.Hangzhou YITU Healthcare Technol Co Ltd, Hangzhou, Peoples R China 3.Zhejiang Canc Hosp, Zhejiang Key Lab Radiat Oncol, Hangzhou, Peoples R China 4.Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China 5.Zhejiang Canc Hosp, Hangzhou, Peoples R China 6.Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China 7.Zhejiang Univ, Inst Immunol, Sch Med, Hangzhou, Peoples R China 8.Zhejiang Chinese Med Sch, Coll Publ Hlth, Dept Med Stat, Hangzhou, Peoples R China 9.900th Hosp, Dept Med Oncol, Fuzhou, Peoples R China |
推荐引用方式 GB/T 7714 | Wang, Wenxian,Huang, Zhangzhou,Yu, Zongyang,et al. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer[J]. FRONTIERS IN ONCOLOGY,2020,10. |
APA | Wang, Wenxian.,Huang, Zhangzhou.,Yu, Zongyang.,Zhuang, Wu.,Zheng, Weijun.,...&Song, Zhengbo.(2020).Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.FRONTIERS IN ONCOLOGY,10. |
MLA | Wang, Wenxian,et al."Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer".FRONTIERS IN ONCOLOGY 10(2020). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论